Author:
Danese Silvio,Fiorino Gionata,Raine Tim,Ferrante Marc,Kemp Karen,Kierkus Jaroslaw,Lakatos Peter L.,Mantzaris Gerassimos,van der Woude Janneke,Panes Julian,Peyrin-Biroulet Laurent
Publisher
Oxford University Press (OUP)
Subject
Gastroenterology,General Medicine
Reference72 articles.
1. European Medicines Agency. CHMP assessment report Remsima [EMA/CHMP/589317/2013]. London: EMA, 2013.
2. European Medicine Agency. [EMA/CHMP/589422/2013]. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf. Accessed October 26, 2016.
3. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
4. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
5. ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
Cited by
207 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献